NOTICE: Thank you for visiting our site. Your experience is important to us. We're upgrading our system to better serve you. During this time, purchases and member logins will be unavailable. Full functionality will be restored by Monday, 29 July.
Christine Bizet
Merck KGaA
Director, Head of Novel Modalities Development EMEA
I am a seasoned leader in the Life Science sector with over two decades of experience in the biotech and pharmaceutical industries, primarily across Europe. My academic background in Biochemistry Engineering laid the foundation for my career, which began at Millipore where I specialized in bioprocessing applications. Over the years, I've expanded my expertise through various roles in sales and field marketing, focusing on innovative technologies for biologics development and manufacturing, including Single Use technologies, process chromatography, and upstream processes.
Currently, I hold a leadership position at Merck KGaA, Darmstadt, Germany in the Life Science division, where I manage a team of Business and Subject Matter Experts; we focus on new biopharmaceutical modalities such as ATMPs and novel antibodies, aiming to deliver cutting-edge solutions that meet the dynamic needs of the industry. Before this, I drove the Process solution strategy deployment and iteration with a global team of Go to Market experts, working in close collaboration with R&D, Marketing and Commercial organizations, to enhance our reach and impact in key markets.
Currently, I hold a leadership position at Merck KGaA, Darmstadt, Germany in the Life Science division, where I manage a team of Business and Subject Matter Experts; we focus on new biopharmaceutical modalities such as ATMPs and novel antibodies, aiming to deliver cutting-edge solutions that meet the dynamic needs of the industry. Before this, I drove the Process solution strategy deployment and iteration with a global team of Go to Market experts, working in close collaboration with R&D, Marketing and Commercial organizations, to enhance our reach and impact in key markets.